Gladys Nunez, Director Amgen Ventures, joined Amgen in 1997 and leads investment diligence for corporate ventures including the Amgen Ventures R&D Seed Fund. As part of her portfolio management activities, she is a board observer on Obsidian Therapeutics, Inversago, Kernal Bio, Caraway Therapeutics, Celsius, and Ribometrix. Based in Amgen’s Cambridge, Ma site she is a member of the external outreach team supporting local outreach/incubator activities, and a member of the cross-site leadership team.
Prior to joining Amgen Ventures in 2014, Gladys spent 12 years in Amgen's Business Development group prospecting and negotiating external alliances. Prior to joining Amgen’s Business Development organization, Gladys worked 7 years in R&D, concurrent between Amgen and AstraZeneca. Gladys holds an MSc in Biochemical Pharmacology from the University of Southampton in England, and BSc from Marist College in Pre-Med.
As an active member of the Mass Bio community, she is a board member and treasurer of Latinos in Bio, a non-profit sponsored by Mass Bio to increase the role of Latinos in the life sciences including career development, education and healthcare disparities. She is also a member of Women in Bio supporting women’s entrepreneurial development and increasing presence of women in venture capital careers.
Outside of work she has twin 15year old boys, plays tennis and enjoys hiking.